A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead’s RNA interference project, are two novel approaches in hep B.
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Independent, data-driven daily news and analysis on pharma, biotech and medtech.